| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 682.0 | 640.4 | 588.0 |
| Other income | 19.9 | 22.4 | 14.7 |
| Total income | 701.9 | 662.8 | 602.7 |
| Profit before exceptional items & tax | 262.0 | 212.2 | 174.1 |
| Profit before tax | 262.0 | 212.2 | 174.1 |
| Net profit | 196.7 | 160.1 | 130.0 |
| Operating margin | 37.3% | 32.0% | 28.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +51.30% |
|---|---|
| Net profit, quarter on quarter | +22.90% |
| Revenue, year on year | +16.00% |
| Operating profit, year on year | +51.90% |
| Operating profit, quarter on quarter | +27.60% |
BSE results filing, NSE: ALIVUS. Figures extracted from the filing.
Alivus Life Sciences Ltd: key numbers
- Share price
- ₹1,395.00
- Market cap
- ₹17,127 Cr
- Revenue (annual)
- ₹2,552 Cr
- Net profit (annual)
- ₹564.5 Cr
- P/E (TTM)
- 28.4×Sector 46.1×
- Promoter holding
- 74.85%-0.02% QoQ
- FII holding
- 5.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alivus Life Sciences Ltd
All →Alivus Life Sciences Employee Stock Options
Alivus Life Sciences allotted 1,95,833 equity shares to an employee who exercised ESOP options under its 2021 scheme. Paid-up capital rises to Rs. 24.59 Crore.
Alivus Life Sciences Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹6,820 Mn (+16.0% YoY), EBITDA ₹2,851 Mn (41.8% margin), PAT ₹1,968 Mn (+51.3% YoY). Non-GPL growth and CDMO pickup drove results.
Alivus Life Sciences Results Update
Alivus Life Sciences reported Q2FY27 revenue of Rs. 6,820 Mn (up 16.0% YoY) and PAT of Rs. 1,968 Mn in a press release. Investors see record EBITDA margins of 41.8% and capex progress at Solapur and Taloja.
Alivus Life Sciences Board Meeting Date
Alivus Life Sciences Ltd has scheduled a Board Meeting on October 29, 2026, to consider and approve its unaudited financial results for the period ended September 30, 2026.
Alivus Life Sciences Other Announcement
The company filed its quarterly shareholding pattern for the period ended September 30, 2026, as per regulatory requirements.
Alivus Life Sciences Legal & Regulatory
Alivus Life Sciences Limited received a GST order for FY 2020-22 involving a tax demand and penalty of Rs. 0.51 Crore. The company is currently assessing an appeal.
- Value
- ₹0.51 Cr